EntreMed (CASI) Rating Reiterated by HC Wainwright

EntreMed (NASDAQ:CASI)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Wednesday. They currently have a $7.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 10.06% from the company’s previous close.

A number of other research firms have also recently weighed in on CASI. ValuEngine upgraded shares of EntreMed from a “hold” rating to a “buy” rating in a report on Monday. BidaskClub upgraded shares of EntreMed from a “hold” rating to a “buy” rating in a report on Wednesday.

How to Become a New Pot Stock Millionaire

NASDAQ CASI traded up $0.21 during trading on Wednesday, reaching $6.36. 502,161 shares of the company’s stock traded hands, compared to its average volume of 411,440. The company has a market capitalization of $509.71, a price-to-earnings ratio of -35.44 and a beta of 0.90. EntreMed has a 12-month low of $0.91 and a 12-month high of $7.20.

EntreMed (NASDAQ:CASI) last posted its earnings results on Thursday, March 29th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.06). equities research analysts expect that EntreMed will post -0.13 earnings per share for the current year.

In related news, major shareholder China Growth Fund Idg-Accel II bought 3,086,418 shares of the stock in a transaction that occurred on Wednesday, March 21st. The stock was bought at an average cost of $3.19 per share, for a total transaction of $9,845,673.42. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Wei-Wu He bought 3,086,419 shares of the stock in a transaction that occurred on Monday, March 19th. The stock was bought at an average price of $3.24 per share, with a total value of $9,999,997.56. Following the completion of the purchase, the director now directly owns 847,527 shares in the company, valued at $2,745,987.48. The disclosure for this purchase can be found here. 24.52% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its stake in EntreMed by 33.4% in the 4th quarter. Renaissance Technologies LLC now owns 150,600 shares of the biotechnology company’s stock worth $489,000 after purchasing an additional 37,700 shares in the last quarter. Millennium Management LLC acquired a new stake in EntreMed during the 4th quarter valued at approximately $137,000. Perceptive Advisors LLC purchased a new position in shares of EntreMed during the 4th quarter valued at approximately $272,000. BlackRock Inc. increased its holdings in shares of EntreMed by 32.6% during the 4th quarter. BlackRock Inc. now owns 386,090 shares of the biotechnology company’s stock valued at $1,254,000 after purchasing an additional 94,984 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of EntreMed by 488.7% during the 4th quarter. Geode Capital Management LLC now owns 225,578 shares of the biotechnology company’s stock valued at $733,000 after purchasing an additional 187,263 shares in the last quarter. Institutional investors own 5.11% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “EntreMed (CASI) Rating Reiterated by HC Wainwright” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3335181/entremed-casi-rating-reiterated-by-hc-wainwright.html.

EntreMed Company Profile

CASI Pharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma.

Receive News & Ratings for EntreMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EntreMed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Positive News Coverage Somewhat Unlikely to Impact Wintrust Financial  Stock Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact Wintrust Financial Stock Price
SAGE Therapeutics  Receives Media Impact Score of 0.08
SAGE Therapeutics Receives Media Impact Score of 0.08
First Citizens BancShares  Given Daily Media Sentiment Rating of 0.22
First Citizens BancShares Given Daily Media Sentiment Rating of 0.22
International Game Technology  Receiving Somewhat Favorable Press Coverage, Accern Reports
International Game Technology Receiving Somewhat Favorable Press Coverage, Accern Reports
Acute Angle Cloud Tops 1-Day Volume of $7.13 Million
Acute Angle Cloud Tops 1-Day Volume of $7.13 Million
FuturXe  Price Tops $0.0093 on Exchanges
FuturXe Price Tops $0.0093 on Exchanges


© 2006-2018 Ticker Report. Google+.